Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
Rhea-AI Summary
Intellia Therapeutics (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on CRISPR-based therapies, has announced its upcoming second quarter 2024 earnings call. The conference call is scheduled for August 8, 2024, at 8 a.m. ET. During this call, the company will present its Q2 2024 financial results and provide operational highlights.
Investors and interested parties can join the call by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international). A live webcast will also be available. A replay of the call will be accessible through Intellia's website after 12 p.m. ET on the same day.
Positive
- Intellia Therapeutics is holding an earnings call, indicating transparency and communication with investors
- The company continues to focus on developing CRISPR-based therapies, maintaining its position in the gene editing field
Negative
- None.
News Market Reaction
On the day this news was published, NTLA declined 4.08%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2024 financial results and operational highlights in a conference call on August 8, 2024, at 8 a.m. ET.
To join the call:
- U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
- Please visit this link for a simultaneous live webcast of the call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on August 8, 2024, at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
ian.karp@intelliatx.com
Lina Li
Senior Director, Investor Relations and Corporate Communications
lina.li@intelliatx.com
FAQ
When is Intellia Therapeutics (NTLA) releasing its Q2 2024 earnings?
How can investors join Intellia Therapeutics' (NTLA) Q2 2024 earnings call?
What will be discussed in Intellia Therapeutics' (NTLA) upcoming earnings call?
Where can I find a replay of Intellia Therapeutics' (NTLA) Q2 2024 earnings call?
